เอกสารอ้างอิง

1. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet 1998; 352(9132): 971-977.
2. Dengue and dengue haemorrhagic fever. WHO fact sheet No. 117. 2002. 3. World Health Organization. Weekly epidemiological record. WHO Geneva 2002; 6(77): 41-48.
3. World Health Organization. Weekly epidemiological record. WHO Geneva 2002; 6(77): 41-48.
4. Gubler DJ. Epidemic dengue/dengue haemorrhagic fever as a public health, social and economic problem in 21th century. Trends Microbiol 2002; 10(2): 100-103.
5. Gubler DJ. Dengue and dengue haemorrhagic fever. Clin Microbiol Rev 1998; 11(3): 480-496.
6. Dengue Fever and Dengue Haemorrhagic fever. Centers for Disease Control and revention. [updated 2002 Feb 13; cited 2004 June 9].
   Available from: http://www.cdc.gov/ncidod/dvbid/dengue.
7. Lin, Y et al. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 1999; 72(12): 9729-9730.
8. Westaway EG, Brinton MA, Gaidamovich SY, Horzinek MC, Igarashi A, Kaariainen L et al. Flaviviridae. Intervirology 1985; 24(4): 183-192.
9. Nimmannitya S. Dengue haemorrhagic fever with unusual clinical manifestations. Asian J Trop Med Public Health 1987; 18: 398-406.
10. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorhage: a pathogenic cascade. Rev Infect Dis 1989; 11 Suppl 4: S830-9.
11. Nelson ER, Bierman HR, Chulajata R. Hematologic phagocytosis in postmortem bone marrows of dengue hamorrhagic fever. (Hematologic phagocytosis in Thai hemorrhagic fever). Am J Med Sci 1966; 252(1): 68-74.
12. Monath TP, Heinz FX. Flaviviruses. In: Fields BM, et.al., editors. Field virology. Lippincott-Raven Publishers, 1996: 961-1034.
13. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18 Suppl 2: 44-47.
14. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn I, Innis BL, Saluzzo J, Hoke CH Jr. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19(23-24): 3179–3188.
15. Huang CY. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 as a potential candidate type 1 virus vaccine. J Virol 2000; 74(7): 3020-3028.
16. Kochel T. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provide protection from viral challengein Aotus monkeys. Vaccine 2002; 18(27): 3166-3173.
17. Porter AG, Davidson EW, Liu JW. Mosquitocidal toxins of Bacilli and their genetic manipulation of effective biological control of mosquitoes. Microbiol Rev 1993; 57(4): 838-861.

18. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990; 44: 649-688.

19. Billoir F, de Chesse R, Tolou H, de Micco P, Gould EA, de Lamballerie X. Phylogeny of the genus Flavivirus using complete coding sequence of arthropod-borne viruses and viruses with no known vector. J Gen Virol 2000; 81(Pt 3): 781-790.

20. Irie K, Mohan PM, Sasaguri Y, Putnak R, Padmanabhan R. Sequence analysis of cloned gengue virus type 2 genome Znew Guinea-C strain). Gene 1989; 75(2): 197-211.

21. Markoff L. In vitro processing of dengue virus structural proteins: cleavage of the pre-membrane protein. J Virol 1989; 63(8): 217-228.

22. Ruiz-Linares A, Cahour A, Despres P, Girard M, Bouloy M. Processing of yellow fever virus polyprotein: role of cellular proteases in maturation of the structural proteins J Virol 1989; 63(10): 4199-4209.

23. Cahour A, Falgout B, Lai CJ. Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions is mediated by viral protease NS2BNS3, whereas NS4A/NS4B may be processed by a cellular protease. J Virol 1992; 66(3): 1535-1542.

24. Falgout B, Chanock R, Lai CJ. Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrphobic signal sequence and the downstream nonstructural protein NS2A. J Virol 1989; 63(5): 1852-1860.

25. Hori H, Lai CJ. Cleavage of dengue virus NS1-NS2A requires an octapeptide sequence at the C terminus of NS1. J Virol 1990: 64(9): 4573-4577.

26. Falgout B, Markoff L. Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplsmic reticulumn. J Virol 1995; 69(11): 7232-7243.

27. Randolph VB, Winkler G, Stolar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 1990; 174(2): 450-458.

28. Falgout B, Pethel M, Zhang YM, Lai CJ. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 1991; 65(5): 2467-2475.

29. Arias CF, Preugschat F, Strauss JH. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 1993; 193(2): 888-899.

30. Lin C, Amberg SM, Chambers TJ, Rice CM. Cleavage at the novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J Virol 1993; 67 (4): 2327-2335.

31. Lobigs M. Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3. Proc Natl Acad Sci USA 1993; 90(13): 6218-6222.

32. Teo KF, Wright PJ. Internal proteolysis of the NS3 protein specified by dengue virus 2. J Gen Virol 1997; 78(Pt 2): 337-341.

33. Li H, Clum S, You S, Ebner KE, Padmanabhan R. The serine protease and RNAstimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J Virol 1999; 73(4): 3108-3116.
34. Wengler G, Wengler G. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 1993; 197(1): 265-273.
35. Warrener P, Tamura JK, Collett MS. RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. J Virol 1993; 67(2): 989-996.
36. Cui T, Sugrue RJ, Xu Q, Lee AK, Chan YC, Fu J. Recombinant dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPaseactivity regulated by the NS5 protein. Virology 1998; 246(2): 409-417.
37. Kapoor M, Zhang L, Ramachandra M, Kusukawa J, Ebner KE, Padmanabhan R. Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. J Biol Chem 1995; 270(32): 19100-19106.
38. Bartholomeusz AI, Wright PJ. Synthesis of dengue virus RNA in vitro: initiation and the involvement of proteins NS3 and NS5. Arch Virol 993;128(1-2): 111-121.
39. Gorbalenya AE, Donchenko AP, Koonin EV, Blinov VM. N-terminal domains of putative helicases of flavi-and pestiviruses may be serine proteases. Nucleic Acids Res 1989; 17(10): 3889-3897.
40. Bazan JF, Fletterick RJ. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 1989; 171(2): 637-639.
41. Chambers TJ, Weir RC, Grakoui A, McCourt DE, Bazan JF, Fletterick RJ et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavage in the viral poly protein. Proc Natl Acad Sci USA 1990; 87(22): 8898-8902.
42. Preugschat F, Yao CW, Strauss JH. In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B and NS3. J Virol 1990; 64(9): 4367- 4374.
43. Wengler G, Czaya G, Färber PM, Hegemann JH. In vitro synthesis of West Nile virus protein indicates that the amino-terminal segment of the NS3 protein contains the active centre of the protease which cleaves the viral polyprotein after multiple basic amino acids. J Gen Virol 1991; 72(Pt 4): 851-858.
44. Falgout B, Miler RH, Lai CJ. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2BNS3 protease activity. J Virol 1993; 67(4): 2034-2042.
45. Clum S, Ebner KE, Padmanabhan R. Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3(Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B. J Biol Chem 1997; 272(49): 30715-30723.
46. Brinkworth RI, Fairlie DP, Leung D Young PR. Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor. J Gen Virol 1999; 80(Pt 5): 1167-1177.

47. Yusof R, Clum S, Wetzel M, Mruthy HM, Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 2000; 275(14): 9963-9969.

48. Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G at al. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J BiolChem 2001; 276(49): 45762-45771.

49. Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C,Panyim S, Katzenmeier G. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation, J Virol 2004; 78(24): 13708-13716.

50. Murthy HM, Clum S, Padmanabhan R. Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J Biol Chem 1999; 274(9): 5573-5580.

51. Murthy HM, JudgenK, DeLucas L, Padmanabhan R. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implication for flaviviral polyprotein processing and drug design. J Mol Biol 2000; 301(4): 759-767.

52. Lesk AM, Fordham WD. Conservation and variability in the structures of serine proteinases of the chymotrypsin family. J Mol Biol 1996; 258(3): 501-537.

53. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87(2): 331-342.

54. Walker B, Lynas JF. Strategies for the inhibition of serine proteases. Cell Mol Life Sci 2001; 58(4): 596-624.

55. Schechter I, Berger A. On the size of the active site in proteases.I. Papain. Biochem Biophysics Res Commun 1967; 27(2): 157-162.

56. Khumthong R, Niyomrattanakit P, Chanprapaph S, Angsuthanasombat C,Panyim S, Katzenmeier G. Steady-state cleavage kinetics for dengue virus type 2 NS2B-NS3(pro) serine protease with synthetic peptides. Prot Pept Letts 2003; 10(1): 19-26.

57. Morris GM, Goodsell DS, Huey R, Hart WE, Halliday S, Belew R, Olson AJ. Autodock Version 3.0.3., The Scripps ResearchInstitute, Molecular Graphics Laboratory, 1999.

58. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19: 639–1662.

59. Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, Katzenmeier G. (2005) Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Commun. 2005; 20;330(4):1237-46.